Ray JD - DermTech G Counsel

DMTKDelisted Stock  USD 0.04  0.02  71.36%   

Insider

Ray JD is G Counsel of DermTech
Age 55
Phone858 450 4222
Webhttps://www.dermtech.com

DermTech Management Efficiency

The company has return on total asset (ROA) of (0.386) % which means that it has lost $0.386 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2175) %, meaning that it created substantial loss on money invested by shareholders. DermTech's management efficiency ratios could be used to measure how well DermTech manages its routine affairs as well as how well it operates its assets and liabilities.
DermTech currently holds 54.39 M in liabilities with Debt to Equity (D/E) ratio of 0.14, which may suggest the company is not taking enough advantage from borrowing. DermTech has a current ratio of 11.95, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about DermTech's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Tamer MDTransMedics Group
56
Bakori DavisCuriositystream
N/A
John CareyTransMedics Group
59
Rob BurkCuriositystream
N/A
Mazin SabraClearpoint Neuro
44
Michael MDOutset Medical
N/A
Stacey PorterOutset Medical
48
Peter WestleyCuriositystream
60
Nabeel AhmedOutset Medical
49
John HendricksCuriositystream
73
Nicole ShannonOutset Medical
N/A
Martin VazquezOutset Medical
53
Brandon PerthuisFulgent Genetics
N/A
James MazzolaOutset Medical
N/A
Waleed MDTransMedics Group
57
JeanOlivier RacineOutset Medical
42
Danilo DAlessandroClearpoint Neuro
40
DABMG FACMGFulgent Genetics
55
Tonya SafferOutset Medical
N/A
Doreen NgFulgent Genetics
N/A
Lawrence MDFulgent Genetics
68
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. The company sells its products primarily to pathology and oncology practitioners. Dermtech operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 255 people. DermTech (DMTK) is traded on NASDAQ Exchange in USA and employs 206 people.

Management Performance

DermTech Leadership Team

Elected by the shareholders, the DermTech's board of directors comprises two types of representatives: DermTech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of DermTech. The board's role is to monitor DermTech's management team and ensure that shareholders' interests are well served. DermTech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, DermTech's outside directors are responsible for providing unbiased perspectives on the board's policies.
Kevin MBA, Treasurer CFO
Burkhard MD, Chief Officer
Todd Wood, Chief Officer
Daniel Visage, Senior Access
Steven Stone, Senior Development
Loren MD, Chief Officer
JD Esq, General Counsel
Ray JD, G Counsel
Jennifer Eilemberg, Chief Officer
Ray Bassi, VP Sales
John MD, CEO Pres
William Zondler, Chief Officer
Steve Kunszabo, Director Relations
Michael Howell, Chief Officer
Bret Christensen, CEO President
Mark Aguillard, Chief Officer
Claudia Ibarra, Chief Officer

DermTech Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is DermTech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Other Consideration for investing in DermTech Stock

If you are still planning to invest in DermTech check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the DermTech's history and understand the potential risks before investing.
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
CEOs Directory
Screen CEOs from public companies around the world
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.